Patent ID: 7615353

Claim:
A method of identifying a human tumor as likely to be responsive or non-responsive to treatment with tivozanib, comprising: (a) measuring, in a sample from the human tumor, the relative expression level of each gene in a predictive gene set (PGS), wherein the PGS consists of the following genes: AIF1, APBB1IP, ARHGAP30, C3AR1, CCR1, CD37, CD53, CD86, CLEC7A, CSF1R, CSF2RB, CTSS, CYBB, DOCK2, EVI2A, EVI2B, FPR3, GMFG, GPR65, HCK, HCLS1, HLA-DMA, IL10RA, ITGB2, LAIR1, LCP1, LCP2, LILRB1, LILRB2, LST1, LY86, MNDA, MS4A6A, MYO1F, NCF4, SLA, SLAMF8, TLR1, TYROBP, PLEK, CYTH4, and PTPRC; and (b) calculating a PGS score according to the algorithm PGS . score = 1 42 * ∑ i = 1 42 ⁢ ⁢ Ei wherein E 1 , E 2 , . . . E 42 are the expression values of the 42 genes in the PGS, and wherein a PGS score below a defined threshold indicates that the tumor is likely to be responsive to tivozanib, and a PGS score above the defined threshold indicates that the tumor is likely to be resistant to tivozanib.